[1]H.S. Rugo, W. Jacot, E. Tokunaga, et al. Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): a detailed safety analysis of the randomized, phase 3 DESTINY-Breast04 trial. 2...
[4] S. Modi, W. Jacot, 376O - Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study. 2023 ESMO 376O....
Prognosis and trends in chemotherapy use for patients with stage IA triple-negative breast cancer(TNBC):A population-based study. 一项基于人群的研究:ⅠA期三阴性乳腺癌(TNBC)患者化疗使用的预后和趋势 讲者:Paolo Tarantino,MD|Dana-Farber Cancer Institute 摘要号:511 Racial/ethnic differences in 21-gene...
3. Hurvitz S, Hegg R, Chung WP, et al. Abstract GS2-02: GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study D...
Breast cancer (BC) is one of the major public health challenges worldwide. Studies that address the new evidence on trends of BC are of great importance for preventing and controlling the occurrence and development of diseases and improving health. The aim of this study was to analyze the outc...
《Translational Breast Cancer Research》、《Gland Surgery》编委 第一/共同第一/通讯作者发表SCI论文40余篇(《Lancet Oncol》等) 回顾DESTINY-Breast04研究的疗效结果,T-DXd开启HER2低表达治疗先河 DESTINY-Breast04(NCT03734029)研究旨在头对头对比T-DXd与研究者选择的方案(TPC)治疗既往转移性疾病阶段接受过1或2线...
Epigenetic scars ofBrca1loss point toward breast cancer cell of origin The two-hit hypothesis suggests that a second mutation is necessary for cancer development in cells with a defective tumor-suppressor gene, such asBRCA1. However, a study now shows that the loss of just oneBrca1allele in ...
Mini Oral session - Breast cancer, early stage 日期:2023年10月23日,星期一 时间:16:30 - 18:00 主席:Ines V. Vaz Luis(Villejuif, Cedex, France) ,Carsten Denkert(Marburg, Germany),Ava Kwong(Hong Kong, Hong Kong PRC) 地点:Bilbao Auditorium - NCC ...
GS02-01 Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Results from TROPION-Breast01 ...
由欧洲肿瘤内科学会(ESMO)主办的2023 ESMO年会将于2023年10月20-24日在西班牙马德里召开。目前,大会常规摘要内容已全部更新,“2023ESMO年会中国医学论坛报学术联播”将持续整理大会重点研究,与大家一起E览盛会! 大会“BREAST CANCER,METASTATIC”领域共设一个优选论文专场与一个简短口头报告专场,汇集转移性乳腺癌治疗最...